These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
4. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches. Hoffmann J; Sommer A J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262 [TBL] [Abstract][Full Text] [Related]
5. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351 [TBL] [Abstract][Full Text] [Related]
6. The role of the androgen receptor in the development and progression of prostate cancer. Jenster G Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Plymate SR; Tennant MK; Culp SH; Woodke L; Marcelli M; Colman I; Nelson PS; Carroll JM; Roberts CT; Ware JL Prostate; 2004 Nov; 61(3):276-90. PubMed ID: 15368471 [TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705 [TBL] [Abstract][Full Text] [Related]
9. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. Vis AN; Schröder FH BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559 [TBL] [Abstract][Full Text] [Related]
10. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. Murillo H; Schmidt LJ; Tindall DJ Cancer Res; 2001 Oct; 61(20):7408-12. PubMed ID: 11606371 [TBL] [Abstract][Full Text] [Related]
11. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626 [TBL] [Abstract][Full Text] [Related]
12. Hormone treatment for prostate cancer: current issues and future directions. Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367 [TBL] [Abstract][Full Text] [Related]
13. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. Edwards J; Bartlett JM BJU Int; 2005 Jun; 95(9):1320-6. PubMed ID: 15892825 [No Abstract] [Full Text] [Related]
14. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Kraus S; Levy G; Hanoch T; Naor Z; Seger R Cancer Res; 2004 Aug; 64(16):5736-44. PubMed ID: 15313914 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555 [TBL] [Abstract][Full Text] [Related]
16. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539 [TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Xie Y; Wolff DW; Lin MF; Tu Y Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Miyamoto H; Altuwaijri S; Cai Y; Messing EM; Chang C Mol Carcinog; 2005 Sep; 44(1):1-10. PubMed ID: 16044418 [TBL] [Abstract][Full Text] [Related]
19. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Manin M; Baron S; Goossens K; Beaudoin C; Jean C; Veyssiere G; Verhoeven G; Morel L Biochem J; 2002 Sep; 366(Pt 3):729-36. PubMed ID: 11971763 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of prostate cancer cell survival after inhibition of AR expression. Cohen MB; Rokhlin OW J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]